Shots:

• The P-III trial (ENHANCE-1) evaluating nebulized ensifentrine as monotx. & added onto a single bronchodilator either a LAMA or a LABA vs PBO for COPD
• The trial met its 1EPs & 2EPs i.e., improvement in lung function, symptoms & QoL measures along with improvements in all subgroups, reduction in exacerbations with a favorable safety profile
• In patients treated with ensifentrine & pooled exacerbation data from (ENHANCE-1 & 2) trial, 36% & 40% reduction in rate of COPD exacerbations over 24wks.; 38% & 41% in the risk of an exacerbation, as measured by time to first exacerbation, was well tolerated over 24 & 48wks. with very few events (≥1%), demographics & disease characteristics were well-balanced b/w treatment groups. The company plans to submit an NDA to the US FDA in H1’23

Ref: Verona Pharma | Image: Verona Pharma

Related News:- Verona Pharma Reports Completion of Enrollment for Ensifentrine in P-III (ENHANCE-2) Trial to Treat COPD